

New Indications

Enbrel (**etanercept**) is now also indicated in juvenile idiopathic arthritis under the following conditions.

Active polyarthritis (rheumatoid factor positive or negative) in children and adolescents, aged 2 to 17 years, who have had an inadequate response to one or more DMARDs;

active extended oligoarthritis in children and adolescents, aged 2 to 17 years, who have had an inadequate response to, or who have proved intolerant to, methotrexate;

active enthesitis related arthritis in adolescents, aged 12 to 17 years, who have had an inadequate response to, or who have proved intolerant to, conventional therapy; and in active psoriatic arthritis in adolescents, aged 12 to 17 years, who have had an inadequate response to, or who have proved intolerant to, methotrexate.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.